Archives Page


Commentary/Short Communication 

The Mainstay of Treatment will be Changed: Cytoreductive Nephrectomy Would Not be Required in Intermediate and Poor Risk Patients with Metastatic Renal Cell Carcinoma Cancer

Ilya Tsimafeyeu

Abstract

To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the first-line treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.

 PDF  |   Full Text
Case Report 

Meningeal Carcinomatosis in a Patient with an Upper Urinary Tract Urothelial Cell Carcinoma

Rosa Maria Martin Diaz, Fernando Moreno Anton, Montserrat Lopez Carreira, Ignacio Juez Martel and Ana Isabel Franco Moreno

Abstract

Meningeal carcinomatosis (MC) is an infrequent of the solid tumors, normally in advanced stages of the disease. It has a very poor prognosis, with a median survival less than 6 month. To our knowledge, meningeal carcinomatosis from upper urinary tract urothelial cell carcinoma (UUT-UCC) has not been reported.

 PDF  |   Full Text
Research Article 

Efficacy and Safety of Sunitinib in Elderly Patients with Advanced Renal Cell Carcinoma at a University Hospital in Japan: Before Immuno-Oncology Therapy Era

Tatsuya Takayama, Akira Fujisaki, Satoshi Ando, Shinsuke Kurokawa and Tatsuo Morita

Abstract

Japan is a front-line country in the coming super-aging society. As with all cancers in the elderly, the frequency of renal cell carcinoma (RCC) is also increasing in Japan. While clinical encounters with elderly patients with advanced RCC increase, these patients are only infrequently entered into clinical trials [3], and efficacy and safety data in this age range are scarce.

 PDF  |   Full Text